For the Inventor, By the Inventor

Enter assignee name

Amsterdam, Netherlands

Abgenomics Cooperatief U.a.

USPTO Granted Patents = 12

CIPO Patents = 1

EPO Patents = 5

Forward Citations = 89

Loading Chart...

Loading Chart...

6 inventors (with patents filed for the assignee):

Rong-Hwa Lin (12 out of 20 patents)

Chung Nan Chang (9 out of 10 patents)

Chiu-Chen Huang (7 out of 12 patents)

4. Pei-Jiun Chen (7 out of 7 patents)

5. Chung-Hsiun Wu (3 out of 6 patents)

6. Pei-Ling Hsu (3 out of 4 patents)

7. Wu Chung-Hsiun (0 patent)

8. Lin Rong-Hwa (0 patent)

9. Hsu Pei-Ling (0 patent)

10. Ronghwa Lin (0 patent)

11. Rong-Hwa Lin (0 patent)

12. Lin Rong-Hwa (0 patent)

13. Wu Chung-Hsiun (0 patent)

14. Hsu Pei-Ling (0 patent)

12 patents: Sort by Forward Citations

1. 10030075 - Methods of treating with anti-PSGL-1 antibodies (2018-07-24),

2. 9631019 - Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies (2017-04-25),

3. 9494574 - T-cell death-inducing epitopes (2016-11-15),

4. 8828397 - Anti-PSGL-1 antibodies and methods of inducing cell death of an activated T cell (2014-09-09),

5. 8663641 - Anti-PSGL-1 antibodies (2014-03-04),

6. 8628775 - Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds (2014-01-14),

7. 8557579 - Screening for modulators of PSGL-1 with respect to T cell or NK cell death (2013-10-15),

8. 8361472 - Anti-PSGL-1 antibodies (2013-01-29),

9. 8298540 - Methods of modulating T cell-mediated immune responses with anti-P-selectin glycoprotein ligand 1 antibodies (2012-10-30),

10. 8287871 - Methods of inducing cell death of an activated T cell with anti-PSGL-1 antibodies (2012-10-16),

11. 7744888 - Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies (2010-06-29),

12. 7604800 - Anti-PSGL-1 antibodies (2009-10-20),

AbGenomics Cooperatief U.A. is a biopharmaceutical company specializing in the discovery and development of innovative antibody therapeutics. With a focus on immunology and immuno-oncology, AbGenomics aims to provide cutting-edge treatments for cancer and autoimmune diseases. Through extensive research and collaborations, the company utilizes advanced technologies to identify and target key disease pathways. AbGenomics is committed to improving patient outcomes and transforming the field of biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

12 Patents

#48 in Amsterdam

#534 in Netherlands

#46,665 in the World

Amsterdam, Netherlands

Abgenomics Cooperatief U.a.

Forward Citations = 89

6 inventors:

Rong-Hwa Lin (12 out of 20 patents)

Chung Nan Chang (9 out of 10 patents)

Chiu-Chen Huang (7 out of 12 patents)

4. Pei-Jiun Chen (7 out of 7 patents)

5. Chung-Hsiun Wu (3 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…